VIVUS (VVUS) Qsymia Prescriptions Fall for Second Week; Promotion Still Ongoing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Arena (ARNA), VIVUS (VVUS) Face Uphill Obesity Battle as Costs Play Key Role
March 21, 2013 6:57 AM EDTArena Pharma (Nasdaq: ARNA) and VIVUS (Nasdaq: VVUS) are fighting the good fight. For profits.
Since the two received FDA approval for their respective obesity pills, Belviq and Qsymia, respectively, the drugs have yet to catch on with patients. Qsymia prescriptions are down 22 percent from a top hit on February 8th, which Belviq is yet to go on sale in the... More
